10X Genomics Inc vs Vanguard International High Dividend Yield ETF — how do they compare? 10X Genomics Inc trades at $57.86 (market cap $7.61B), while Vanguard International High Dividend Yield ETF trades at $104.6. Which is the better fit depends on your goals.
| TXG | VYMI | |
|---|---|---|
Market Cap | $7.61B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $58.57 | $105.05 |
52-Week Low | $11.34 | $82.92 |
Enterprise Value | $7.14B | — |
Signals from Pluang's Aura AI — not financial advice
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →